$170.80
0.78% yesterday
Nasdaq, Dec 24, 09:02 pm CET
ISIN
IE00B4Q5ZN47
Symbol
JAZZ

Jazz Pharmaceuticals Plc Stock price

$170.80
-10.10 5.58% 1M
+62.69 57.99% 6M
+47.65 38.69% YTD
+47.07 38.04% 1Y
+13.61 8.66% 3Y
+13.52 8.60% 5Y
+28.06 19.66% 10Y
+153.07 863.34% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+1.33 0.78%

New AI Insights on Jazz Pharmaceuticals Plc Insights AI Insights on Jazz Pharmaceuticals Plc

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$10.4b
Enterprise Value
$13.7b
Net debt
$3.3b
Cash
$2.0b
Shares outstanding
60.7m
Valuation (TTM | estimate)
P/E
negative | 20.8
P/S
2.5 | 2.4
EV/Sales
3.3 | 3.2
EV/FCF
11.1
P/B
2.6
Financial Health
Equity Ratio
34.1%
Return on Equity
13.7%
ROCE
5.0%
ROIC
2.7%
Debt/Equity
1.4
Financials (TTM | estimate)
Revenue
$4.2b | $4.3b
EBITDA
$1.1b | $709.8m
EBIT
$453.9m | $656.5m
Net Income
$-368.5m | $499.8m
Free Cash Flow
$1.2b
Growth (TTM | estimate)
Revenue
4.1% | 6.0%
EBITDA
-17.1% | -47.6%
EBIT
-35.5% | -9.7%
Net Income
-179.6% | -10.8%
Free Cash Flow
12.5%
Margin (TTM | estimate)
Gross
88.5%
EBITDA
26.4% | 16.5%
EBIT
10.9%
Net
-8.9% | 11.6%
Free Cash Flow
29.8%
More
EPS
$-6.0
FCF per Share
$20.4
Short interest
9.5%
Employees
3k
Rev per Employee
$1.5m
Show more

Is Jazz Pharmaceuticals Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Jazz Pharmaceuticals Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

21x Buy
88%
3x Hold
13%

Analyst Opinions

24 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

Buy
88%
Hold
13%

Financial data from Jazz Pharmaceuticals Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
4,158 4,158
4% 4%
100%
- Direct Costs 478 478
13% 13%
12%
3,679 3,679
3% 3%
88%
- Selling and Administrative Expenses 1,772 1,772
28% 28%
43%
- Research and Development Expense 809 809
6% 6%
19%
1,098 1,098
17% 17%
26%
- Depreciation and Amortization 644 644
4% 4%
15%
EBIT (Operating Income) EBIT 454 454
36% 36%
11%
Net Profit -368 -368
180% 180%
-9%

In millions USD.

Don't miss a Thing! We will send you all news about Jazz Pharmaceuticals Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jazz Pharmaceuticals Plc Stock News

Neutral
PRNewsWire
7 days ago
DUBLIN , Dec. 17, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events: Zanidatamab HERIZON-GEA-01 Investor Webcast on Friday, January 9, 2026 The Company will host an investor webcast on Friday, January 9, 2026, at 6:30 a.m. PT / 3:30 p.m.
Neutral
PRNewsWire
20 days ago
New interim results from the EpiCom trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomes Eight abstracts, including four late-breaking abstracts, underscore Jazz's continued commitment to the epilepsy community and advancing the comprehensive treatment for rare forms of epilepsy For U.S. media and invest...
Positive
FXEmpire
20 days ago
Jazz Pharmaceuticals PLC (JAZZ) shares up 352% since Big Money bought big in 2015.
More Jazz Pharmaceuticals Plc News

Company Profile

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Bruce Cozadd
Employees 2,800
Founded 2005
Website www.jazzpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today